A small biotech trying to develop an Avastin biosimilar to treat wet AMD has run into a setback.
Outlook Therapeutics withdrew its BLA for bevacizumab, the active compound in Roche/Genentech’s Avastin cancer therapy, after the FDA requested additional information to complete the application, the biotech said Tuesday. Outlook plans to...
